Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22235351 | 0.93 | PDE4D (0.30) | PDE4D | |
| SCHEMBL22235347 | 0.93 | PDE4D (0.30) | PDE4D | |
| SCHEMBL22235348 | 0.93 | PDE4D (0.30) | PDE4D | |
| SCHEMBL29728910 | 0.93 | PDE4D (0.30) | PDE4D | |
| SCHEMBL22235658 | 0.87 | PDE4D (0.35) | PDE4DKAT2BALDH1A1KDM4E | |
| SCHEMBL22235666 | 0.82 | — | — | |
| SCHEMBL24357109 | 0.79 | PDE4D (0.34) | PDE4DKDM4E | |
| SCHEMBL22235213 | 0.78 | NPC1 (0.32) | ALDH1A1GAAKDM4E | |
| SCHEMBL22236197 | 0.78 | NPC1 (0.32) | ALDH1A1GAAKDM4E | |
| SCHEMBL22235212 | 0.76 | KDM4E (0.32) | PDE4DKAT2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125771-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-04-28 | — | — | US | disclosed |
| EP-3911653-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150366-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125771-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, HDGF | PDE4D 3456/4885KAT2B 2069/4885ALDH1A1 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.